阿托伐他汀强化降脂对急性脑梗死患者血清hs-CRP、NSE及MMP-3水平的影响  

Effect of atorvastatin for intensive lipid-lowing on the serum levels of hs-CRP,NSE and MMP-3 in patients with acute cerebral infarction

作　　者：覃星悦[1] 肖海[1] 农媛[1] 

机构地区：[1]贵港市人民医院神经内科,广西贵港537100

出　　处：《华夏医学》2017年第5期20-23,共4页Acta Medicinae Sinica

摘　　要：目的:探讨阿托伐他汀强化降脂治疗急性脑梗死(ACI)的临床疗效,以及对患者血清超敏C反应蛋白(hs-CRP)、神经元特异性烯醇化酶(NSE)及基质金属蛋白酶-3(MMP-3)水平的影响。方法:选择我院收治的ACI患者116例,按照不同的用药量分为研究组和对照组,每组各58例。两组均给予脑梗死常规治疗。在此基础上,对照组应用阿托伐他汀钙片20 mg/d,研究组应用阿托伐他汀钙片40 mg/d,疗程均为12周。观察对比两组临床疗效、治疗前、治疗12周后血脂水平、血清hs-CRP、NSE、MMP-3水平及药物不良反应情况。结果:研究组总有效率为93.10%,高于对照组的79.31%(P<0.05)。治疗后两组患者血浆HDL-C比较差异无统计学意义(P>0.05);治疗后两组患者血浆总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)均低于治疗前,且研究组低于对照组(P<0.05)。两组治疗后血清hs-CRP、NSE及MMP-3水平均低于治疗前,且研究组低于对照组(P<0.05)。两组药物不良反应发生率比较差异无统计学意义(P>0.05)。结论:阿托伐他汀强化降脂在ACI患者中具有良好的应用效果,可以有效调节血脂,降低血清hs-CRP、NSE及MMP-3水平。Objective： To investigate the clinical efficacy of atorvastatin for intensive lipid-lowering therapy on patients with acute cerebral infarction（ ACI）,and its influence in the levels of hs-CRP,NSE and MMP-3. Methods： 116 ACI patients in our hospital were divided into the study group and control group according to the different dosage of medications administered in patients with 58 patients in each. All patients were administered conventional treatment. On this basis,patients in the control group added atorvastatin calcium tablets,20 mg per day; while patients in the study group were treated with additional atorvastatin calcium tablets,40 mg per day. And the treatment course lasted 12 weeks for all patients. The clinical efficacy of both groups was observed. In addition,the levels of lipid,serum hs-CRP,NSE and MMP-3,and adverse drug reactions of patients in both groups before treatment and 12 weeks after treatment were compared. Results： The total efficacy for the study group was 93.1%,significantly higher than 79.31% for the control group（ P〈0.05）. There was no statistical difference of HDL-C in both groups after treatment（ P〉0. 05）; TC,TG and LDL-C of patients were lower than those before treatment,also lower than those of patients in the control group（ P〈0.05）. Serum hs-CRP,NSE and MMP-3 levels were lower than those before the treatment,and lower than those of the control group（ P〈0.05）. And there was no statistical difference for the incidence of drug adverse reaction in both group（ P〉0. 05）. Conclusion：Atorvastatin for intensive lipid-lowering therapy is effective on ACI patients. It can effectively adjust serum lipid,reduce serum levels of hs-CRP,NSE and MMP-3.

关 键 词：阿托伐他汀 降脂 急性脑梗死 HS-CRP 

分 类 号：R743.33[医药卫生—神经病学与精神病学]